Possibilities of multi-vector therapy with N-acetylcysteine in the treatment of acute bronchitis

Мұқаба

Дәйексөз келтіру

Толық мәтін

Ашық рұқсат Ашық рұқсат
Рұқсат жабық Рұқсат берілді
Рұқсат жабық Рұқсат ақылы немесе тек жазылушылар үшін

Аннотация

Acute bronchitis (AB) is an acute inflammation of the bronchial tissue, which often occurs in association with upper respiratory tract infections in the absence of chronic bronchopulmonary diseases. Etiologic agent of AB is rarely determined, but in most cases, it is caused by viruses and much less often by bacteria. If the patient has chronic bronchopulmonary pathology (for example, bronchial asthma, chronic bronchitis, chronic obstructive pulmonary disease, bronchiectasis, cystic fibrosis), acute inflammation of the tracheobronchial tree is an exacerbation of the chronic disease, and not AB. It is fundamentally important to distinguish between these clinical situations due to the difference in approaches to their therapy and possible outcomes. In the treatment of OB, symptomatic therapy is used most often. In that case leading role is played by mucoactive drugs, although in some cases it may be necessary to prescribe other groups of medicines – antibiotics, inhaled glucocorticosteroids, antitussives. The aim of the article: to highlight the possibilities of multi-vector therapy of this disease by means of N-acetylcysteine use.

Толық мәтін

Рұқсат жабық

Авторлар туралы

Marina Makarova

Pirogov Russian National Research Medical University; Research Institute of Pulmonology; Yudin City Clinical Hospital

Хат алмасуға жауапты Автор.
Email: mma123@list.ru
ORCID iD: 0000-0003-4913-087X
SPIN-код: 7153-0940

MD, PhD (Medicine), Associate Professor of the Department of Pulmonology of the Institute of Continuous Education and Professional Development; Researcher of the Department of Intensive Care and Respiratory Failure; Pulmonologist of the Department of Respiratory Medicine

Ресей, 1/6, Ostrovityanov St., Moscow, 117513; 28/10, Orekhovy Blvd., Moscow, 115682; 4, Kolomensky Dr., Moscow, 115446

Andrey Belevsky

Pirogov Russian National Research Medical University

Email: pulmobas@yandex.ru
ORCID iD: 0000-0001-6050-724X
SPIN-код: 7313-8885

MD, Dr. Sci. (Medicine), Professor, President of the Russian Respiratory Society, Chief External Expert Pulmonologist of the Department of Healthcare of the Government of Moscow, Head of the Department of Pulmonology of the Institute of Continuous Education and Professional Development

Ресей, 1/6, Ostrovityanov St., Moscow, 117513

Stanislav Krasovsky

Research Institute of Pulmonology; Academician Bochkov Medical and Genetic Research Center

Email: sa_krasovsky@mail.ru
ORCID iD: 0000-0001-9642-0947
SPIN-код: 3385-6489

MD, PhD (Medicine), Senior Researcher of the Department of Cystic Fibrosis; Leading Researcher of the Scientific and Clinical Department

Ресей, 28/10, Orekhovy Blvd., Moscow, 115682; 1, Moskvorechye St., Moscow, 115478

Әдебиет тізімі

  1. Клинические рекомендации. Острый бронхит. Общероссийская общественная организация «Российское научное медицинское общество терапевтов», Российское респираторное общество, Межрегиональная ассоциация специалистов респираторной медицины (МАСРМ). Рубрикатор клинических рекомендаций Минздрава России. 2024. ID: 891_1. Доступ: https://cr.minzdrav.gov.ru/preview-cr/891_1 (дата обращения – 15.05.2025). [Clinical guidelines. Acute bronchitis. Russian Scientific Medical Society of Internal Medicine, Russian Respiratory Society, Interregional Association of Respiratory Medicine Specialists. Rubricator of clinical guidelines of the Ministry of Healthcare of Russia. 2024. ID: 891_1. URL: https://cr.minzdrav.gov.ru/preview-cr/891_1 (date of access – 15.05.2025) (In Russ.)].
  2. Li P, Yin R, Cheng J, Lin J. Bacterial biofilm formation on biomaterials and approaches to its treatment and prevention. Int J Mol Sci. 2023;24(14):11680. PMID: 37511440. PMCID: PMC10380251. https://doi.org/10.3390/ijms241411680
  3. Olson ME, Ceri H, Morck DW, Buret AG, Read RR. Biofilm bacteria: Formation and comparative susceptibility to antibiotics. Can J Vet Res. 2002:66(2):86–92. PMID: 11989739. PMCID: PMC226988.
  4. Blasi F, Page C, Rossolini GM, Pallecchi L, Matera MG, Rogliani P, Cazzola M. The effect of N-acetylcysteine on biofilms: Implications for the treatment of respiratory tract infections. Respir Med. 2016;117:190–97. PMID: 27492531. https://doi.org/10.1016/j.rmed.2016.06.015
  5. Zheng CH, Ahmed K, Rikitomi N, Martinez G, Nagatake T. The effects of S-carboxymethylcysteine and N-acetylcysteine on theadherence of Moraxella catarrhalis to human pharyngeal epithelial cells. Microbiol Immunol. 1999;43(2):107–13. PMID: 10229264. https://doi.org/10.1111/j.1348-0421.1999.tb02381.x
  6. Santus P, Signorello JC, Danzo F, Lazzaroni G, Saad M, Radovanovic D. Anti-inflammatory and anti-oxidant properties of N-acetylcysteine: A fresh perspective. J Clin Med. 2024;13(14):4127. PMID: 39064168. PMCID: PMC11278452. https://doi.org/10.3390/jcm13144127
  7. Raghu G, Berk M, Campochiaro PA, Jaeschke H, Marenzi G, Richeldi L et al. The multifaceted therapeutic role of N-acetylcysteine (NAC) in disorders characterized by oxidative stress. Curr Neuropharmacol. 2021;9(8):1202–24. PMID: 33380301. PMCID: PMC8719286. https://doi.org/10.2174/1570159X19666201230144109
  8. Chen H, Zhou H, Luo C, Zong K, Fu Y, Li W et al. Efficacy of treatment with N-acetylcysteine inhalation for AECOPD: A propensity-score-matched cohort study. Clin Respir J. 2023;17(10):1038–47. PMID: 37621062. PMCID: PMC10543066. https://doi.org/10.1111/crj.13690
  9. Rhee CK, Lim SY, Lee W-Y, Jung JY, Bum PY, Lee CY et al.; Korean Pulmonary Rehabilitation Study Group. The effect of nebulized N-acetylcysteine on the phlegm of chronic obstructive pulmonary disease: The NEWEST study. BMC Pulm Med. 2024;24(1):434. PMID: 39223526. PMCID: PMC11369990. https://doi.org/10.1186/s12890-024-03243-y

Қосымша файлдар

Қосымша файлдар
Әрекет
1. JATS XML
Жүктеу
2. Fig. Flow-volume curve in an observed patient

Жүктеу (16KB)
Метадеректер

© Bionika Media, 2025